Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma

BACKGROUND: Compared with single‐drug TACE, our previous phase III study demonstrated that triple‐drug transarterial chemoembolization (TACE) prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). The aim of this study was to find which patients can benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales: He, MinKe, Li, Qing, Shen, JingXian, Tan, GuoSheng, Li, QiJiong, Lai, JiaYing, Wei, Wei, Zhang, YaoJun, Zou, RuHai, Chen, MinShan, Guo, RongPing, Shi, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675716/
https://www.ncbi.nlm.nih.gov/pubmed/31207163
http://dx.doi.org/10.1002/cam4.2355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675716/
https://www.ncbi.nlm.nih.gov/pubmed/31207163
http://dx.doi.org/10.1002/cam4.2355

Ejemplares similares